Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNA, U4 small nuclear 14, pseudogene (RNU4-14P)** is annotated as a pseudogene of U4 small nuclear RNA. U4 small nuclear RNAs are genuine components of the spliceosome, the large ribonucleoprotein machinery responsible for pre-mRNA splicing in eukaryotes[2]. However, as a "pseudogene," RNU4-14P does **not encode a functional RNA product and is not known to participate in biological pathways**. Pseudogenes are generally regarded as non-functional relics derived from once-functional genes, often lacking regulatory regions or carrying disabling mutations. There is no evidence that RNU4-14P serves as a therapeutic target, disease biomarker, or is implicated in any drug interactions. Therefore, **RNU4-14P is not considered a valid molecular target, and its annotation in any context implying therapeutic or functional relevance is likely incorrect**. **Additional context:** - Some confusion may arise because functional U4 small nuclear RNAs (such as those encoded by RNU4-2 or related genes) are indeed critical for pre-mRNA splicing and disruptions in their function are disease-associated (particularly with neurodevelopmental disorders)[1][3]. Pseudogenes like RNU4-14P, however, lack such relevance because they do not produce the corresponding active RNA molecule. - If a therapeutic, regulatory, or disease association involving U4 snRNA is intended, one should refer to functional genes like RNU4-2, not RNU4-14P[1][3]. **Summary:** RNU4-14P is a non-functional pseudogene and not a valid therapeutic or biological target. If the query was meant to refer to the active U4 small nuclear RNA (such as encoded by RNU4-2), please clarify for the appropriate canonical entry.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U4 small nuclear 14, pseudogene (RNU4-14P).